MTP looks to Simponi to secure dominant rheumatoid arthritis position in Japan
This article was originally published in Scrip
Mitsubishi Tanabe Pharma (MTP) is expecting Simponi (golimumab) to help it maintain the leading position in the rheumatoid arthritis sector in Japan, where the subcutaneously injected TNF-alpha inhibitor has become the first once-monthly therapy in this class to be launched in the country.
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.